2 completed, 2 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Terminated 2, Completed 1 |
Follow NUC-3373: new trials by email Literature Review of NUC-3373 trials Research Report on NUC-3373
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer Fosifloxuridine Nafalbenamide, Leucovorin, Irinotecan - Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Terminated | NuCana plc | 180 | 2023-04-18 | 2025-09-12 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment NUC-3373 + leucovorin, NUC-3373, NUFOX - Colorectal Cancer, Colorectal Neoplasms | Phase 1 / Phase 2 | Completed | NuCana plc | 111 | 2018-10-05 | 2025-04-23 |
| NUC-3373 in Advanced Solid Tumours NUC-3373 - Cancer | Phase 1 | Completed | University of Oxford | 62 | 2016-01-01 | 2024-02-14 |
Neoplasms (3) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1)
NuCana plc (3) · University of Oxford (1)
United Kingdom (4) · France (2) · United States (2) · Germany (1) · Italy (1) · Spain (1)
Elisabeth Oelmann, MD PhD (1) · Elisabeth Oelmann, MD, PhD (1) · Sarah P Blagden, PhD, FRCP (1)
2015 (1), 2017 (1)